Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

521.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
51 52 Next >
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
Via Benzinga
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point. 
Via The Motley Fool
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
Via Investor's Business Daily
Topics Stocks
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
Via Benzinga
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Smart Money Is Betting Big In REGN Options
Via Benzinga
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap. 
Via Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year. 
Via Investor's Business Daily
Topics Stocks
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
Via Investor's Business Daily
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.